Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

110 results about "Disease biomarker" patented technology

Biomarkers as health and disease predictors. Biomarkers are used to predict serious illnesses such as diabetes and cardiovascular disease. Each individual biomarker indicates whether there is a disease or health state and can be combined to provide a detailed picture of how healthy a person is and whether or not a diagnosis needs to be made.

Metabonomics data batch correction method based on multi-kernel learning

The invention discloses a metabonomics data batch correction method based on multi-kernel learning, and belongs to the cross technical field of bioinformatics and analytical chemistry. According to the method, the multi-kernel learning technology is utilized, the advantages of different kernel functions are fused in a self-adaptive mode, a model conforming to data reality is constructed, complex drift characteristics of metabolite signals are accurately captured, and efficient and accurate normalization processing of metabonomics data is achieved. Compared with traditional data standardization methods such as SVR and LOESS, the method has the advantages that the performance is excellent in the aspect of reducing the metabolite peak intensity variability, and the data stability is remarkably improved. In the subsequent multivariate statistical analysis, the classification accuracy is greatly improved, the comparability among different batches of data is also remarkably enhanced, reliable data support can be provided for discovery of disease biomarkers, and the method plays a key role in large-scale metabonomics research.
Owner:DALIAN CHEM DATA SOLUTION TECH CO LTD

Marker combination for detecting Alzheimer's disease and application of marker combination in single molecule detection

PendingCN119086929AAccurately assess performanceImprove reliabilityColor/spectral properties measurementsBiological testingNeurofilament lightMolecular array
The invention relates to the technical field of biological detection, and particularly discloses a marker combination for detecting Alzheimer's disease, which comprises the following markers: beta amyloid protein 1-40, beta amyloid protein 1-42, phosphorylated Tau217 protein, phosphorylated Tau181 protein, phosphorylated Tau231 protein, neurofilament light chain protein and colloidal fiber acidic protein. The invention also discloses application of the marker combination for detecting the Alzheimer's disease in single molecule detection. The application comprises the following steps: S1, preparing standard solutions with different concentrations of the markers; s2, detecting the standard solutions with different concentrations of each marker by adopting a single molecule array analysis technology, and counting corresponding single molecule signal numbers; and S3, drawing a standard curve of each marker according to the single molecule signal numbers corresponding to the standard solutions with different concentrations of each marker. The method has the advantages that the overall performance of the AD disease biomarker combination can be accurately evaluated, and the reliability and accuracy of AD disease markers in clinical application are improved.
Owner:CHENGDU FUREN BIOTECHNOLOGY CO LTD

Parkinson's disease biomarker, detection reagent and application

The invention discloses a Parkinson's disease biomarker, a detection reagent and application, and the Parkinson's disease biomarker has the advantages of high sensitivity and low misdiagnosis rate, and can be effectively used for early diagnosis of Parkinson's disease and risk prediction of adverse events. The biomarker at least comprises one of the following indexes: a concentration ratio of C16 ceramide to C24 ceramide (Ce16: 0 / Cer24: 0), a concentration ratio of C18 ceramide to C24 ceramide (Ce18: 0 / Cer24: 0), a concentration ratio of C24: 1 ceramide to C24 ceramide (Ce24: 1 / Cer24: 0), and a combined index Cer16: 0, Cer18: 0, and a ratio of the total concentration of Cer24: 1 to the concentration of Cer24: 0 (Conc (Ce16: 0 + Cer18: 0 + Cer24: 1) / Conc (Ce24: 0).
Owner:BOHAI (TIANJIN) MEDICAL TECHNOLOGY CO LTD +1

Disease marker expression network reconstruction feature key point determination method

A disease marker expression network reconstruction feature key point determination method belongs to the technical field of disease markers, and comprises the following steps: processing a to-be-detected tissue sample to obtain marker multi-dimensional data; performing wavelet decomposition on the marker multi-dimensional data to obtain a marker multi-scale coefficient, wherein the marker multi-scale coefficient comprises a reference component, a high-frequency component, an intermediate-frequency component and a low-frequency component; constructing a frequency domain incidence matrix based on the marker multi-scale coefficient, wherein the frequency domain incidence matrix represents the incidence intensity between different frequency components; constructing a network reconstruction model according to the frequency domain incidence matrix and multi-scale weights, wherein the multi-scale weights comprise a reference weight, a high-frequency weight, an intermediate-frequency weight and a low-frequency weight; the existing marker expression network reconstruction and key node identification method has some limitations, and the technical problem that the method for determining the reconstruction feature key points of the disease marker expression network in the prior art is not accurate enough is solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD

Ocular disease marker identification using multi-spectral imaging

PendingUS20250295308A1Image enhancementImage analysisBiomarker identificationRetinal Disorder
A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.
Owner:AI-SPECTRAL TECHNOLOGY CORP

Deep neural network-based disease full-period management system

The invention discloses a disease full-period management system based on a deep neural network, and the system comprises a collection time sequence planning module, a disease biomarker data collection module, and a compliance standard assessment module. The method comprises the following steps: acquiring previous disease diagnosis elements such as specific disease category proportion and attack frequency of each patient in each time window of a historical period from a target hospital patient platform, analyzing a disease period adaptive value according to the previous disease diagnosis elements, and further determining an acquisition time sequence plan when the patient is discharged from a hospital. And the compliance standard evaluation module is used for acquiring a compliance evaluation value of the discharge collection time sequence plan of each patient in the current period, judging whether the compliance reaches the standard or not, sending out an early warning prompt to the substandard patient, and recording the substandard patient as a to-be-analyzed patient. And the disease outcome state analysis module is used for analyzing the disease outcome states of the to-be-analyzed patients at each acquisition time point, carrying out early warning prompt according to the analysis result, and realizing accurate management and monitoring of the whole period of the diseases of the patients through multi-module cooperation.
Owner:XIAN CHAOQIAN INTELLIGENT TECH CO LTD

Application of Prevotella copri as children metabolism-related fatty liver disease biomarker and therapeutic target

The invention discloses application of Prevotella copri as a children's metabolism-related fatty liver disease (MASLD) biomarker and a therapeutic target, relates to the fields of medical microbiology and metabonomics, and explores biological characteristics of the Prevotella copri and an action mechanism of the Prevotella copri in children's metabolism-related fatty liver disease (MASLD). The invention also analyzes the effect of Prevotella copri and its metabolite 5-aminovaleric acid in the development of children's metabolism-related fatty liver disease (MASLD), and provides a basis for developing a method for treating metabolism-related fatty liver disease (MASLD) based on intestinal microorganisms. According to the present invention, the Prevotella copri is subjected to intragastric administration to the mouse fed with the high fat diet, such that the liver fat change and the intestinal flora disorder aggravating are found; the metabolite 5-amino valeric acid of the Prevotella copri can be used for aggravating the adiposis of the liver cells. Therefore, the Prevotella copri and the metabolite 5-aminovaleric acid of the Prevotella copri can be used as a biomarker and a therapeutic target for diagnosis, treatment, prognosis evaluation or drug screening of the MASLD (Metabolism-related Fatty Liver Disease) of children.
Owner:SHANGHAI INST OF PEDIATRIC RES

Ocular disease marker identification using multi-spectral imaging

PCT designated stageWO2025194268A1Image enhancementImage analysisBiomarker identificationRetinal Disorder
A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.
Owner:AI-SPECTRAL TECHNOLOGY CORP

Immunochromatography test strip based on nano-robot as well as preparation method and application of immunochromatography test strip

The invention discloses an immunochromatography test strip based on a nano-robot as well as a preparation method and application thereof. The immunochromatography test strip comprises a bottom plate, and a sample pad, filter paper, a nitrocellulose membrane and absorbent paper which are sequentially overlapped and adhered to the bottom plate, when in use, an FPSN (at) Ab buffer solution is dropwise added on the surface of the sample pad; the FPSN (at) Ab buffer solution is prepared from Fe3O4 (at) mPDAamp; the preparation method comprises the following steps: preparing an mSiO2 (at) Nanozyme nano composite material and an antibody to be marked; the Fe3O4 (at) is mPDAamp; the mSiO2 (at) Nanozyme nano composite material is nano particles with an asymmetric structure, one end of the asymmetric structure is a core-shell structure, the core is Fe3O4, the shell is mesoporous polydopamine particles, the other end is rod-like mesoporous SiO2, and noble metal nano particles are loaded on the surfaces of Fe3O4 and mesoporous SiO2; according to the invention, the nano-robot is used as the probe to construct the immunochromatography test strip, so that the detection sensitivity and the detection speed of the test strip are improved, the binding efficiency between the probe and the to-be-detected object is optimized, and the problem that in the prior art, accurate detection of disease markers is difficult to realize under the conditions of small sample size and low concentration is solved.
Owner:XI AN JIAOTONG UNIV

Alzheimer's disease biomarker based on brain metabolite and use thereof

An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Retinal disease biomarker prediction by stacking slices of 3D OCT image to reshape into 2D image and applying trained feature extractor and CNN

Deep learning methods and systems for detecting biomarkers within optical coherence tomography volumes using such deep learning methods and systems are provided. Embodiments predict the presence or absence of clinically useful biomarkers in OCT images using deep neural networks. The lack of available training data for canonical deep learning approaches is overcome in embodiments by leveraging a large external dataset consisting of foveal scans using transfer learning. Embodiments represent the three-dimensional OCT volume by “tiling” each slice into a single two dimensional image, and adding an additional component to encourage the network to consider local spatial structure. Methods and systems, according to embodiments are able to identify the presence or absence of AMD-related biomarkers on par with clinicians. Beyond identifying biomarkers, additional models could be trained, according to embodiments, to predict the progression of these biomarkers over time.
Owner:RGT UNIV OF CALIFORNIA +1

Disease marker binding pocket identification method

The invention provides a disease marker binding pocket identification method, and belongs to the technical field of disease marker binding pockets, and the method comprises the following steps: firstly, constructing a simulation system containing a disease marker, and carrying out 100-500ns molecular dynamics simulation; a conformation change track is collected and subjected to normalization processing; carrying out decomposition calculation on the sampled conformation, and analyzing a conformation cluster with relatively high frequency; calculating structural parameters of amino acid residues, and screening a region with relatively high flexibility as a potential binding site; analyzing the solvent accessibility and electrostatic characteristics of the sites; identifying a temporary binding pocket through the water molecule distribution density; performing principal component analysis to extract a conformation change mode; constructing an amino acid residue interaction network, and screening a stable binding pocket based on indexes such as binding free energy, conformational stability and pocket comprehensive performance evaluation; the method solves the problem that most existing methods only consider static structural characteristics of molecules and neglect the influence of dynamic change of protein conformation on binding pocket formation.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD

Preparation method of VP@UiO-66-NH2 / Ag NPs composite SERS chip and application thereof in detection of A beta protein

The application discloses a preparation method of a VP@UiO-66-NH2 / Ag NPs composite SERS chip and application thereof in A beta protein detection, and is characterized by comprising the following steps: synthesizing a VP-graphite paper base by a chemical vapor transport method on a surface of a graphite paper to obtain a VP-graphite paper base; synthesizing a UiO-66-NH2 layer on the surface of the VP-graphite paper base by a solvothermal method to obtain a VP@UiO-66-NH2 composite base; and finally, placing the composite base in an ion sputtering instrument, uniformly sputtering silver nanoparticles on the surface of the composite base, taking out the composite base, and obtaining the VP@UiO-66-NH2 / Ag NPs composite SERS chip, wherein the VP@UiO-66-NH2 / Ag NPs composite SERS chip has the advantages of high sensitivity, good stability and uniformity, controllable preparation process, low cost, application in Alzheimer's disease biomarker detection, high specificity in identification and quantitative analysis of A beta 40 and A beta 42 proteins, fast response and good stability.
Owner:YUYAO PEOPLES HOSPITAL

Preparation and application of HVC NPs for the diagnosis and treatment of Parkinson's disease

This invention discloses a method for preparing HVC NPs for the diagnosis and treatment of Parkinson's disease and their applications. The probe HV in the HVC NPs responds to H2O2 and viscosity, utilizing near-infrared fluorescence imaging capabilities to achieve real-time monitoring of Parkinson's disease biomarkers, helping us better understand the occurrence and development of Parkinson's disease. With the assistance of RVG29, the HVC NPs effectively cross the blood-brain barrier. The curcumin within them can reduce cell apoptosis, lower oxidative stress levels, scavenge excess reactive oxygen species, combat inflammation, and reduce α-synuclein aggregation, demonstrating effective anti-Parkinson's disease effects at the cellular and experimental animal levels. This nanomaterial provides a new strategy for integrated research on the diagnosis and treatment of Parkinson's disease.
Owner:SHANXI MEDICAL UNIV

Methods and devices for detection of orthogonal classes of disease biomarkers

In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.
Owner:INNOTECH PRECISION MEDICINE INC

Biomarkers and methods for measuring and monitoring inflammatory disease activity

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.
Owner:LABORATORY CORPORATION OF AMERICA HOLDINGS INC +1

Methods and products for biomarker identification

PendingCN119998461AMicrobiological testing/measurementDNA preparationMedicineBiomarker identification
Methods and products for discovering disease biomarkers and diagnosing disease are provided. RNA or cDNA samples are typically dominated by sequences from highly expressed genes, which can negatively impact the analysis of the samples. The present invention provides methods and products for preparing a treated nucleic acid sample having a more uniform sequence distribution, which can then be analyzed to find and detect disease biomarkers. Methods of protecting RNA in a blood sample are also provided. These methods can be combined to further improve the ability to find and detect disease biomarkers.
Owner:WOBAO GENOMICS CO LTD

Pretreatment method of specimen

To provide a pretreatment method of a specimen for accurately and simply performing quantification of a biomarker protein by preventing aggregation of a disease biomarker protein in the specimen or adsorption thereof to a container.SOLUTION: A pretreatment method of a specimen containing an aggregation biomarker protein, includes a step of mixing the specimen with sodium dodecyl sulfate (SDS). A quantification method of an aggregation biomarker protein in a specimen, includes the steps of: mixing the specimen with sodium dodecyl sulfate (SDS); and after the mixing step, specifically detecting and quantifying the biomarker protein in the specimen.SELECTED DRAWING: None
Owner:THE UNIV OF TOKYO +1

Preparation and application of nanoparticle HVC NPs for diagnosis and treatment of Parkinson's disease

The invention discloses a preparation method and application of nanoparticles HVC NPs for diagnosis and treatment of Parkinson's disease. The probe HV in the HVC NPs can respond to H2O2 and viscosity, the near-infrared fluorescence imaging capability is played, real-time monitoring of the Parkinson's disease biomarker is achieved, and people are helped to better explore occurrence and development of Parkinson's disease. HVC NPs effectively permeates the blood brain barrier under the assistance of RVG29, curcumin in HVC NPs can relieve apoptosis, reduce the oxidative stress level, eliminate excessive active oxygen, resist inflammation, reduce alpha-syn aggregation and the like, and the effect of effectively resisting Parkinson's disease is shown at the cell and experimental animal level. The nano material provides a new strategy for integrated research on diagnosis and treatment of Parkinson's disease.
Owner:SHANXI MEDICAL UNIV

Kit and method for detecting Alzheimer's disease biomarker p-Tau181 protein

The invention discloses a kit and a method for detecting a biomarker p-Tau181 protein of Alzheimer's disease, and belongs to the technical field of in vitro detection.The kit comprises a magnetic bead working solution composed of magnetic beads labeled by a p-Tau181 antibody and a buffer solution, the visual non-magnetic microsphere working solution is composed of visual non-magnetic microspheres labeled by total tau antibodies and a buffer solution, the size of magnetic beads is 1-10 [mu] m, and the size of the visual non-magnetic microspheres is 1-10 [mu] m. The scheme has the advantages of high sensitivity, good specificity and the like, the detection limit can be reduced to 0.01 pg / mL, and a non-invasive and reliable detection means is provided for the Alzheimer's disease.
Owner:WUHAN YZY MEDICAL SCI & TECH

Stellate microneedle

PCT designated stageWO2026096342A1MicroneedlesMedical devicesExosomeDiagnosis cancer
Provided herein is technology relating to obtaining and testing biological samples for disease biomarkers and particularly, but not exclusively, to hydrogel-coated microneedles, arrays of hydrogel-coated microneedles, and related methods of making stellate microcolumns and hydrogel-coated microneedles and using the hydrogel-coated microneedles for capturing exosomes from subject tissues for diagnosing diseases such as cancer.
Owner:THE RGT UNIV OF MICHIGAN

Biomarker HLA-DOA for sepsis-related diseases and use thereof

The present invention relates to a biomarker HLA-DOA for sepsis-related diseases and a use thereof. The present invention provides a use of HLA-DOA or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases in a subject.
Owner:CHENGDU CELENOV BIOTECH CO LTD

Methods and devices for detection of orthogonal classes of disease biomarkers

In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.
Owner:INNOTECH PRECISION MEDICINE INC

CRISPR (clustered regularly interspaced short palindromic repeats) Cas13a mutant as well as coding gene, expression plasmid, protein expression system and application thereof

The invention is suitable for the technical field of bioengineering, and provides a CRISPR Cas13a mutant, and a coding gene, an expression plasmid, a protein expression system and application thereof. Compared with the wild type CRISPR Cas13a (Cas13a-WT), the amino acid residue at the 967th site of the amino acid sequence of the CRISPR Cas13a mutant Cas13a-Y967E is mutated into an amino acid which keeps the specificity of the amino acid sequence and has improved RNA (Ribonucleic Acid) shearing activity. The amino acid sequences of the Cas13a-WT and the Cas13a-Y967E are respectively as shown in SEQ ID NO. 1 and SEQ ID NO. 2, and the Cas13a-WT and the The RNA shearing activity of the Cas13a-Y967E is remarkably improved, the specificity of the Cas13a-Y967E is kept, target pathogens or disease biomarkers can be recognized and detected more accurately and efficiently in the fields of pathogen detection, disease diagnosis and treatment and the like, and missing detection and false detection are reduced.
Owner:JILIN UNIVERSITY +1

Large-scale D-protein screening method based on thermal proteomics technology

The invention discloses a D-protein large-scale screening method based on a thermal proteomics technology, which comprises the following steps: step 1, respectively adding a protein treating agent or not adding the protein treating agent into cells to obtain a D-protein up-regulation group and a D-protein blank group; step 2, obtaining a thermal stability differential protein list by using a thermal proteomics technology; step 3, acquiring a stereoisomeric protein list by utilizing a heterogeneous retrieval technology; step 4, comparing and analyzing the heat stability differential protein list and the stereoisomeric protein list to obtain potential D-protein; and step 5, based on an APM enzyme digestion technology, obtaining the D site of the potential D-protein. The large-scale identification method of the D-protein with high throughput and high coverage is realized through a thermal proteomics technology, the D-amino acid site can be accurately positioned, and the method has important significance on exploration of disease biomarkers, exploration of pathogenesis of major diseases and the like.
Owner:NANKAI UNIV

A filter coating composition for fluorescence detection and its preparation method

This invention discloses a filter coating composition for fluorescence detection and its preparation method, relating to the fields of optical materials and biodetection technology. The composition is formulated by compounding optical functional powders, polymer substrates, dispersants, and additives in specific proportions, exhibiting high transmittance, narrow wavelength selectivity, excellent weather resistance and mechanical stability. It can accurately filter excitation light and stray light, improving the sensitivity and specificity of fluorescence detection. The filter coating composition and its preparation method for fluorescence detection also provide a simple, cost-effective manufacturing process suitable for large-scale production, particularly applicable to gene sequencing and immunochemistry. It addresses the problems of poor wavelength selectivity, weak stability, and high cost associated with traditional filters, making it suitable for fluorescence detection scenarios such as Alzheimer's disease biomarkers. Balancing accuracy, stability, and economy, it has broad application prospects in the field of in vitro diagnostic reagents.
Owner:SHENZHEN DALU BIOTECHNOLOGY CO LTD

Method for sample quality assessment

The present invention relates to methods for obtaining a biological sample with improved quality. It encompasses the identification of markers or proteins in a biological sample that are altered due to variations in sample collection, handling, and processing. The method can also be used to correct variations in the measurement results of disease biomarkers. Additionally, if it is determined that the sample collection method is inconsistent with a predetermined protocol, the method can allow for the rejection of a sample or group of samples as needed. Other advantages useful to those skilled in the art are described herein.
Owner:SOMALOGIC OPERATING CO INC

Parkinson's disease cognitive disorder early biomarker and application thereof, and Parkinson's disease intelligent analysis system

The invention provides an early biomarker for cognitive impairment of Parkinson's disease, application of the early biomarker and an intelligent analysis system for Parkinson's disease. The biomarker is a GALC gene. The intelligent analysis system for the early biomarkers of the cognitive impairment of the Parkinson's disease comprises a data integration module and a data analysis module. The data integration module is used for acquiring a gene detection result, an olfactory test score and neuroimaging data of the Parkinson's disease biomarker; and the data analysis module is used for analyzing the influence of gene variation of the Parkinson's disease biomarker on olfactory dysfunction and cognitive decline of the Parkinson's disease patient by adopting a structural equation model SEM based on the multi-modal data set. According to the application, through confluence analysis of multi-modal data, by combining genetics, neuroimaging and clinical evaluation, the rs8005172 site variation of the GALC gene is taken as an early biomarker of cognitive impairment of Parkinson's disease, so that PD patients with high cognitive decline risk can be accurately identified.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Diagnostic agent and method for alzheimer's disease

The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Owner:TEMASEK LIFE SCIENCES LABORATORY LTD

Novel high-sensitivity electrochemical immunosensor for detecting Tau-441 protein

The invention discloses a high-sensitivity Tau-441 electrochemical immunosensor based on a nano material synergistic amplification effect as well as a preparation method and application of the high-sensitivity Tau-441 electrochemical immunosensor. According to the sensor, a silk-screen printing electrode (SPE) is used as a substrate, a PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode is used as a sensing platform, and electron transfer is promoted by using the large specific surface area and excellent conductivity of the PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode. Meanwhile, gold-modified magnetic nanoparticles (Fe3O4-coated AuNPs) are prepared as a signal probe, and the magnetic separation and enrichment function of Fe3O4 and the biocompatibility and catalytic activity of the gold nanoparticles are combined. The sandwich immune complex is constructed by adopting a homogeneous reaction mode, so that the mass transfer resistance is effectively reduced, and the detection time is shortened. The sensor has an extremely low detection limit (19.68 fgmL <-1 >) and a wide linear range on an Alzheimer's disease marker Tau-441, is high in specificity and good in stability, and is suitable for early-stage rapid screening of human plasma samples.
Owner:南宁桂电电子科技研究院有限公司 +1